

Clinical Standards Board

**Minutes of the meeting held on
Thursday 8th August 2019
1- 3.30 pm
St James House, Pendleton Way, Salford**

Present:

Name	Title	Organisation	Representing	Oct	Dec	Feb	Apr	Jun	Aug
Dr Helen Burgess (HB)	GP MO Prescribing lead	NHS Manchester CCGs	Chair/GPs	✓	✓	✓	✓	✓	✓
Dr Pete Budden (PB)	GP Prescribing lead	Salford CCG	FMESG						
Jane Brown (JB)	Chair of the GM Pharmacy LPN	GM Pharmacy LPN	NHSE Local Professional Network						
Petra Brown (PeB)	GM MH Medicines Optimisation Strategic Lead	GM MH	GM Mental Health Organisations	✓	✓	✓	✓	✓	✓ JW
Dr Richard Darling (RD)	GP Prescribing Lead	Heywood, Middleton and Rochdale CCG	PaGDSG						
Siobhan Farmer (SF)	Public Health Consultant & Screening and Immunisation Lead	Greater Manchester Health & Social Care Partnership	GM Public Health	✓	A	✓	✓	A	A
Kate Rigden (KR)	Deputy Chief Finance Officer	NHS Oldham CCG	CCG finance leads		✓	A	✓	✓	✓
Jay Hamilton (JH)	Program Development Lead	GM AHSN	Health Innovation Manchester (HIM)	✓	✓	A	✓	A (Dep)	✓
Lindsay Harper (LH)	Director of Pharmacy	Salford Royal FT	FMESG						
Dr Ann Harrison (AH)	GP MO Prescribing lead	Trafford CCG	GPs	✓	✓	✓	✓	✓	✓
Robert Hallworth	Specialist Cancer	NHSE	PaGDSG	✓	✓	✓	✓	✓	✓

(RH)	Pharmacist								
Peter Howarth (PH)	Head of Medicines Management	Tameside & Glossop CCG	CCG MO leads	A (KL)	A (LB)	✓	✓	✓	✓
Vacant seat			Secondary Care Clinicians						
Leigh Lord (LL)	Locality Lead Pharmacist	NHS Trafford CCG	CCG MO leads	✓	✓	✓	✓	A	✓
Peter Marks	LPC Board Member	GM LPC	Community Pharmacy		✓	✓	✓	✓	✓
Karen O'Brien	Controlled Drugs Accountable Officer	Greater Manchester Health & Social Care Partnership	GM HSCP	✓	✓	✓	✓	✓	✓
Margaret O'Dwyer (MOD)	Director of Commissioning and Business Delivery / Deputy Chief Officer	Bury CCG	CCG Commissioning leads	✓	✓	✓	✓	✓	✓
Steve Simpson (SS)	Chief Pharmacist	Bolton FT	Vice-Chair/ Chief pharmacists	✓	✓	✓	✓	✓	A
Charlotte Skitterall (CS)	Chief Pharmacist	Manchester FT	HCDSG	A	A	A	A	A	A
Claire Vaughan (CV)	Head of MO	Salford CCG	HCDSG	✓	✓	A	✓	✓	A
Dr Sanjay Wahie (SW)	Clinical Director	NHS Wigan CCG	GPs	✓	✓	✓	✓	✓	✓
Sue Dickinson (SD)	Director of Pharmacy	RDTC		✓	✓	✓	✓	✓	✓
Monica Mason (MM)	Head of Prescribing Support	RDTC		✓	✓	✓	✓	✓	✓
Andrew Martin/ Sarah Jacobs/ Kathryn Griffiths/ Anna Pracz (SJ)	MO Pharmacists	GM Shared Service		✓ AM	✓ SJ/ AM/ KG	✓ KG/ AM	✓ AM	✓ KG	✓ AM

1. General Business

1.1 Apologies

Apologies had been received in advance as noted above.

1.2 Declarations of Interest

HB declared a DOI for item 4 and left the room for this item which was chaired by MO'D.

There were no interests raised that were relevant to this agenda. Members were reminded that it is their responsibility to submit any relevant information, to ensure the DOI register (published on the GMMMGM website and considered at each meeting) is kept up to date at all times.

1.3 Minutes and actions from the June meeting

- Update from MO summit and implications for GMMMGM TOR: Actions from summit and date for October event to be shared as soon as possible (JCT). It was noted that clinician attendance was limited at the last event due to insufficient notice. Suggestions/comments regarding CSB ToR and membership from all members to be emailed to MM within the next two weeks
- Neuropathic pain guidance - GMMMGM to continue with technical review (PaGDSDG). Submit topic to RMOC for production of accompanying supporting information (KO'B)
- Drugs for wAMD - Paper to be submitted to Oct CSB agenda (KL)
- GM rebate scheme policy - Paper to be submitted to Oct CSB agenda (KL)
- Adult ADHD SCP: commissioning implications - Noted that work is being undertaken outside of GMMMGM, but (MO'D, PB) agreed to communicate outcome of annual monitoring commissioning arrangement discussion, so that the GMMMGM SCP can be amended and approved for publication to reflect this decision.

Items received for GMMMGM ratification

2. GMMMGM Work plan 2019/20

The 2019/20 GMMMGM workplan, narrative and proposed monitoring schedule were presented for approval to submit to DoCs. Some minor amendments were suggested. It was agreed that the work stream assurance reports currently in development would be shared at the Sept Chairs meeting

Action: AM to amend and send to MO'D for DoCs submission by Friday 9th August 2019

3. OTC Policy

CSB supported the proposed actions which would lead to a soft launch of the GM position in September; amendments as discussed would be communicated to GM CCGs for their approval following the August meeting. A baseline monitoring report will be submitted to the October CSB meeting.

Action: LB to submit the agreed papers to DoCs and DFCOs around ongoing maintenance costs for the toolkit. LB/AM to submit final versions of relevant documents to RDTTC for website hosting. Baseline monitoring report to be submitted to October CSB

4. Gluten Free Policy

This item was chaired by MO HB left the room.

CSB considered revisions to the GMMMGM gluten free prescribing guidance following changes to the NHSE guidance and the drug tariff. CSB were asked to approve this recommendation to be taken forward as policy by DoCs. CSB did not approve this request, and instead asked that the

authors return to scope the current positions taken by all GM CCGs as they are aware that a number of CCGs already have a zero prescribing policy, and that a GM position should support the majority position. CSB asked that CCGs communicate their current gluten free prescribing positions to the joint commissioning team.

Action: SW(JCT) to seek current CCG positions for all GM CGs and ascertain whether a nil prescribing position is possible across all GM CCGs

- 5. Final recommendation: Dibotermin alfa (InductOs®) for the treatment of non-union fracture in adults (CCG commissioned)** – CSB approved the draft commissioning recommendation for submission to DoCs. Whilst this agent is below the financial threshold for communication to DoCs, the proposed use includes the off-license use of this agent.

Action: MM to submit to DoCs Sept meeting

6. GMMMG OAB Guidance

CSB noted that this guideline has undergone a technical review and has been expanded to include the treatment of men. There is no commissioning or financial impact expected from the implementation of this guidance, and it was approved for addition to the GMMMG website for use. It was agreed that CSB ask that DoCs review their commissioning arrangements to reflect the revised pathway

Action: MM to upload to website and communicate update to DoCs.

Outputs from GMMMG Subgroups

7. Pathways and Guidelines Development Subgroup Minutes (July)

Action: Noted – add to GMMMG website

8. Formulary and Managed Entry Subgroup Minutes (July)

Action: Noted – add to GMMMG website

9. High Cost Drugs Subgroup Minutes (June + draft actions July)

Action: Noted – add to GMMMG website

Governance

10. Framework for assessment of health outcomes modelling

CSB to look to HIM and/or NHSE for support to undertake the necessary health modelling required.

Action: MM to liaise with JH

Monitoring and assurance

11. GM biosimilar uptake assurance report

CSB discussed the content of this paper and the accompanying RMOc Adalimumab Update paper and noted that whilst some improvement was seen in most GM organisations, some showed no improvement at all. CSB noted that a “lessons learned” paper was in development and that the newly formed High Cost Drug Strategic Group are meeting soon to discuss this.

Action: Update to return to Oct CSB meeting

12. Update on Wound Care Formulary Project (July 2019)

It was agreed that the project lead (CP) be invited to attend the October CSB to provide a deliver a full progress update

Action: MM to invite CP to the October meeting

13. GM antimicrobial prescribing assurance report

CSB noted that TOR had been shared for comment and would be approved by Chairs in Sept or at Oct CSB. Baseline paper highlighting the current positions of all GM CCGs and the improvement plans agreed/in development to be submitted to Oct CSB (KO'B/KG)

Communication from Subgroups and Associated Committees

14. GM CCG lead pharmacists – the minutes of the recent meeting of this group would be shared in due course

15. GM Chief Pharmacists - updates were given on the “transfer of care around medicines” project.

16. GM Mental Health Trusts - JW attended in place of PB and raised two issues to CSB; the issue of clozapine as a repeat medicine, to which CSB suggested this be raised with NHSDig/EMIS as a system issue, and the issue of medicines via private prescription resulting long term NHS care, to which it was suggested that a conversation with the locality lead commissioner may be appropriate.

17. NHSE Local Professional Network – no representative present

18. Health Innovation Manchester – it was noted that two fixed term appointments had been made by HIM to support SMASH dashboard development and other work streams. The next Industry/HIM meeting is to be held in October and a GMMMG rep was requested.

19. GM Pharmaceutical Industry Partnership Group Meeting – no update

20. RMOC – update as per most recent newsletter

AOB

Nil

Date of next meeting: Thursday 10th October 2019, 1- 3.30pm